<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2F8FFA18-3477-4D4D-BB19-496C194318FB"><gtr:id>2F8FFA18-3477-4D4D-BB19-496C194318FB</gtr:id><gtr:name>O. I. Medical Limited</gtr:name><gtr:address><gtr:line1>REDLANDS 3-5 , TAPTON HOUSE ROAD</gtr:line1><gtr:city>SHEFFIELD</gtr:city><gtr:postCode>S10 5BY</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F8FFA18-3477-4D4D-BB19-496C194318FB" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2F8FFA18-3477-4D4D-BB19-496C194318FB</gtr:id><gtr:name>O. I. Medical Limited</gtr:name><gtr:address><gtr:line1>REDLANDS 3-5 , TAPTON HOUSE ROAD</gtr:line1><gtr:city>SHEFFIELD</gtr:city><gtr:postCode>S10 5BY</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>173556.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FC9A7412-783F-408D-840C-03F5BF1BE4A1"><gtr:id>FC9A7412-783F-408D-840C-03F5BF1BE4A1</gtr:id><gtr:firstName>Andrea</gtr:firstName><gtr:surname>Marsden</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710360"><gtr:id>140652F0-8A2A-4772-B4EC-0DC30088F7D9</gtr:id><gtr:title>Single Use Transcervical Occlusive Plug System (SUTOPS)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710360</gtr:grantReference><gtr:abstractText>The world population continues to expand at an alarming rate bringing with it poverty &amp;amp;
hardship. Female sterilisation is the most widely used practical method of family planning
worldwide. However an ideal method does not exist. J Guillebaud ? Contraception your
questions answered 4th Edition 2004. Approximately 180 women of reproductive age around
the world are protected from unintended pregnancy by sterilisation (Ross et al 1985). Female
sterilisation by laparoscopic occlusion of the fallopian tubes is a widely used method for
family planning because of its proven safety &amp;amp; effectiveness (Ms Swain H &amp;amp; Brodie MF
2006). However laparoscopic procedures which involve the use of abdominal instrumentation
&amp;amp; require general anaesthetic are not without major complications (Jansen F W et al 1997 &amp;amp;
Esobedo et al 1980) @ 1 per 1,000 procedures in USA although they rarely cause death.
However low morbidity &amp;amp; mortality rates have to be revised in light of the enormous numbers
of procedures @ 1 million &amp;amp; in USA (Tuland T 1977) &amp;amp; 14 million globally per annum. The
current hysteroscopic method/product is expensive @ &amp;pound;450 per tube, is not reversible &amp;amp;
cannot be used for the treatment of Hydrosalpinx to improve the conception rate. OI Medical
Ltd is developing the international intellectual property for a low cost novel hysteroscopic
method which has a high chance of being reversible &amp;amp; is looking to prove the concept &amp;amp; use it
in small clinical tests. The economic &amp;amp; social benefits are considerable with a market worth
&amp;pound;7B p.a. &amp;amp; with unwanted pregnancy, children have a higher incidence of psychiatric
disorders, educational deficiencies, delinquency, criminal behaviour &amp;amp; alcoholism (Ney 1978
&amp;amp; 1979).</gtr:abstractText><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710360</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>